 TEL AVIV, Israel, July 23, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. Nasdaq: NSPR, developer of the CGuardTM Embolic Prevention Stent System EPS device for the treatment of Carotid Artery Disease CAD and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Companys U.S. registration C-Guardian trial of CGuard EPS. 